Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research
NAVIGATOR is a double-blind, randomized, placebo controlled, 2x2 factorial design, multi-national clinical outcome trial in patients with documented cardiovascular disease or at high cardiovascular risk who have impaired glucose tolerance.
The trial evaluating separately the impact of nateglinide and valsartan on progression to diabetes and on a core and extended composite cardiovascular outcome. 9518 patients were randomised between 2002 and 2003 with results expected in 2010.
NAVIGATOR is funded by Novartis.